Oramed Pharmaceuticals (ORMP) Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: affirmative, alongside, automatically, Binyamin, bore, calendar, case, charge, classified, clerical, consent, conversion, converted, convertible, conveyance, CRO, debited, decided, Dev, dividend, estate, expanding, expert, extend, extent, February, fifty, final, Frontier, fundamental, holder, InClin, institutional, Itochu, Koseido, Lido, lidocaine, Master, negative, occurrence, Oishi, organization, original, ownership, pari, passu, Percentage, placement, processing, prohibit, PSU, Rabi, rank, real, recapitalization, receipt, redeem, redeemed, redemption, reevaluation, refinance, refinanced, refinancing, registered, registering, resignation, Rest, retain, retire, retired, retirement, ROW, RPA, shareholder, signatory, Silex, structure, subordinate, subordinated, subordination, successor, system, Tama, Territory, tranche, varying, wholly, World, ZTlido

Removed: applicable, assume, initiate, intend, partial

From filing 10-Q 2024 Q3

Financial report summary

Competition

vTv Therapeutics • Terns Pharmaceuticals

Management Discussion

The table and discussion that follows includes a comparison of our results of operations and liquidity and capital resources for the years ended December 31, 2023 and 2022. For a comparison of our results of operations and financial condition for the year ended December 31, 2022 and the year ended December 31, 2021, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 6, 2023.
Revenues consist of proceeds related to the HTIT License Agreement that are recognized on a cumulative basis when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, through the expected product submission date by HTIT of June 2023, using the input method.
Revenues for the year ended December 31, 2023 decreased by 50% to $1,340,000, compared to $2,703,000 for the year ended December 31, 2022. The decrease was mainly due to recognition of revenues until the product submission date by HTIT in June 2023.